IRVINE, Calif.--(BUSINESS WIRE)--Toro Neurovascular, an innovative medical device company, is excited to announce the successful treatment of the first patient using its Toro 88 SuperBore Aspiration Catheter as part of a first-in-man clinical study. The procedure, performed by esteemed neurosurgeon Nobuyuki Sakai, MD, DMSc., and his staff at Shimizu Hospital in Japan, marks a key milestone in Toro’s mission to transform stroke treatment through cutting-edge technology..

加利福尼亚州欧文市（商业新闻短讯）--创新医疗器械公司Toro Neurovascular兴奋地宣布，作为首次人体临床研究的一部分，首次使用其Toro 88 SuperBore抽吸导管成功治疗了第一名患者。该手术由尊敬的神经外科医生Nobuyuki Sakai，MD，DMSc进行。，和他在日本清水医院的工作人员，标志着Toro通过尖端技术改变中风治疗任务的一个关键里程碑。。

Dr. Sakai, President of Seijinkai Shimizu Hospital, commented, “Toro 88’s performance was exceptional, particularly in accessing the intricate anatomy of the cerebral vasculature. Its ability to efficiently remove large clot burden and navigate challenging conditions is impressive. I am pleased to be part of this study, which has the potential to significantly enhance stroke treatment and improve patient outcomes.”.

西津开清水医院院长Sakai博士评论道：“Toro 88的表现非常出色，特别是在获取复杂的脑血管解剖结构方面。它能够有效地消除大量凝块负担并应对具有挑战性的条件，这一点令人印象深刻。我很高兴成为这项研究的一部分，这项研究有可能显着增强中风治疗并改善患者预后。”。

Toro’s innovative catheter technology is poised to establish a new standard for navigating complex neurovascular anatomy. Featuring MicroFlex™ Technology, a reinforced micro-wire design, the Toro 88 catheter was engineered from the ground up for enhanced control and navigation through tortuous, challenging conditions.

Toro的创新导管技术有望为复杂的神经血管解剖导航建立新的标准。Toro 88导管采用MicroFlex™技术和增强型微丝设计，从头开始设计，可在曲折、充满挑战的条件下增强控制和导航。

Its advanced support profile is designed to provide exceptional maneuverability, precision, and efficient access the M1 segment of the middle cerebral artery (MCA). With a vessel-matched 0.088-inch lumen, Toro 88 aims to enable complete clot ingestion, potentially transforming patient outcomes..

其先进的支撑轮廓旨在提供出色的可操作性，精确度和有效的大脑中动脉（MCA）M1段。Toro 88拥有与0.088英寸管腔相匹配的血管，旨在实现完全的凝块摄入，从而可能改变患者的预后。。

“Our goal is to improve patient outcomes through innovation, and we are excited to showcase how our technology may streamline clot access and removal,” said Hyung Posalit, CEO of Toro Neurovascular. “We are committed to developing high-performance devices that make a meaningful difference in stroke patient outcomes.

Toro Neurovascular首席执行官Hyung Posalit说：“我们的目标是通过创新改善患者的预后，我们很高兴展示我们的技术如何简化凝块的获取和清除。”。“我们致力于开发高性能设备，从而对中风患者的预后产生有意义的影响。

This milestone is a testament to our ongoing efforts to create real-world benefits for patients.”.

这一里程碑证明了我们正在努力为患者创造现实世界的利益。”。

Toro is driven by the potential to make a profound impact on thrombectomy procedures, and the first use of the Toro 88 SuperBore Catheter in Japan marks a critical step toward realizing this vision. The company believes that its devices will offer physicians an improved first-line stroke treatment, possibly delivering faster and more effective results.

Toro是由对血栓切除术产生深远影响的潜力所驱动的，Toro 88 SuperBore导管在日本的首次使用标志着实现这一愿景的关键一步。该公司相信，其设备将为医生提供改进的一线中风治疗，可能会提供更快，更有效的结果。

Toro catheters have the potential to significantly elevate the standard of stroke care and expand access to stroke therapy in developing regions, subject to regulatory approvals..

经监管部门批准，Toro导管有可能显着提高中风护理标准，并扩大发展中国家中风治疗的机会。。

The Toro 88 SuperBore Aspiration Catheter is not commercially available for use in any country.

Toro 88 SuperBore抽吸导管在任何国家都不可商购。

About Toro Neurovascular:

关于Toro Neurovascular：

Toro Neurovascular is at the forefront of designing advanced medical devices that incorporate cutting-edge technology to improve the standard of care for stroke patients worldwide.

。